Gene
APOE
Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Why this gene matters most
APOE is the single largest-effect common variant for Alzheimer’s disease and arguably the most consequential common longevity variant.
The ApoE protein is a key lipid-transport apolipoprotein in plasma and a major lipid carrier in the brain. The three alleles encode proteins that differ at two amino-acid positions, with the ε4 form having weaker lipid affinity and faster catabolism.
Beyond Alzheimer’s
- ApoE ε4 increases cardiovascular disease risk (modest).
- ApoE ε4 is under-represented in centenarian cohorts — these adults survive in spite of, not because of, ε4.
- ApoE ε2 over-representation in centenarians; large population effect.
Actionable implications for ε4 carriers
The 2024 Lancet Commission and other groups emphasise that ε4 carriers benefit more from modifiable lifestyle interventions:
- BP control.
- Sleep optimisation (especially OSA screening).
- Hearing-aid use if hearing loss.
- Exercise (zone 2 + resistance + cognitive engagement).
- Mediterranean-style diet.
- Avoid traumatic brain injury (contact sports, heading).
- Anti-amyloid antibody decisions involve genotype-specific ARIA risk.
Testing
Widely available (23andMe, Galleri, AncestryDNA, direct clinical). Some carriers prefer not to know; pre-test counselling is valuable.
Related entries
APOE genotype (concept), Alzheimer's disease, Cognitive decline, FINGER trial.
References
- Liu, C.-C. et al. Apolipoprotein E and Alzheimer disease. Nat. Rev. Neurol. 9, 106–118 (2013).